Chemotherapy Protocols and Infusion Sequence 2022
DOI: 10.1007/978-3-031-10839-6_1
|View full text |Cite
|
Sign up to set email alerts
|

Polypharmacy in Cancer Therapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 137 publications
0
1
0
Order By: Relevance
“…The hazard factors for polypharmacy in patients with cancer are the number of health problems, inpatient admissions, and prescriptions to manage adverse drug reactions with adjunctive medications. The repercussions of polypharmacy in oncology are adverse drug reactions, DDIs, incremental hazards of morbidity, and mortality [105][106][107].…”
Section: Qt Interval Extending Ddis With Anticancer Agentsmentioning
confidence: 99%
“…The hazard factors for polypharmacy in patients with cancer are the number of health problems, inpatient admissions, and prescriptions to manage adverse drug reactions with adjunctive medications. The repercussions of polypharmacy in oncology are adverse drug reactions, DDIs, incremental hazards of morbidity, and mortality [105][106][107].…”
Section: Qt Interval Extending Ddis With Anticancer Agentsmentioning
confidence: 99%